Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668811 · ClinicalTrials.gov registry record · Phase 2
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
A Phase 2 study, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00668811 is a Phase 2 study that has completed, run by Medstar Health Research Institute. The registered enrollment target is 23 participants.
The verdict
NCT00668811, a Phase 2 study, has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited, new therapies are desperately needed. This study is designed to see if Sutent following therapy with radioactive iodine will target cancer cells and delay disease progression better than standard therapy alone. Newly diagnosed patients, who are scheduled to receive radioactive iodine as part of their standard care are possible candidates. By entering into this study, participants agree to take oral Sutent for approximately two years after completing standard therapy. During this time, study participants will be followed closely by their doctor.
Interventions
- DRUG SU011248, Sutent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668811
The ClinicalTrials.gov registry entry for NCT00668811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SU011248, Sutent is the first listed.
NCT00668811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668811 about?
NCT00668811 is a clinical study titled "Sutent Adjunctive Treatment of Differentiated Thyroid Cancer". This study is comparing a drug called Sutent with standard of care treatment for people with advanced thyroid cancer. Because advanced thyroid cancer is becoming increasingly common and effective treatment options are limited, new therapies are desperately needed. This study is designed to see if S...
What is the current status of trial NCT00668811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-04. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00668811?
The interventions under investigation include: SU011248, Sutent (DRUG).
Who is sponsoring clinical trial NCT00668811?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.